NEOS Investment Management LLC Has $1.07 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

NEOS Investment Management LLC lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 40.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,765 shares of the company's stock after selling 17,143 shares during the quarter. NEOS Investment Management LLC's holdings in Moderna were worth $1,071,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in MRNA. UniSuper Management Pty Ltd grew its position in Moderna by 69.3% in the fourth quarter. UniSuper Management Pty Ltd now owns 50,953 shares of the company's stock valued at $2,119,000 after purchasing an additional 20,862 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Moderna in the 4th quarter valued at about $770,000. Crowley Wealth Management Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at about $41,000. LPL Financial LLC raised its holdings in Moderna by 274.6% during the fourth quarter. LPL Financial LLC now owns 367,878 shares of the company's stock worth $15,296,000 after acquiring an additional 269,682 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Moderna during the fourth quarter valued at approximately $4,441,000. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 4.2 %

Shares of NASDAQ:MRNA traded down $1.19 on Tuesday, reaching $27.16. 11,625,208 shares of the company's stock were exchanged, compared to its average volume of 6,890,880. Moderna, Inc. has a twelve month low of $26.80 and a twelve month high of $170.47. The company has a fifty day moving average of $34.60 and a 200-day moving average of $43.84. The company has a market capitalization of $10.50 billion, a price-to-earnings ratio of -2.93 and a beta of 1.86.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Berenberg Bank upped their price objective on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of "Hold" and a consensus target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.